Streetbeat News

Products Services

ARM

INTC

MU

QCOM

TSM

Intel Corp (NASDAQ:INTC) is receiving takeover proposals from chip companies like Arm Holdings (NASDAQ:ARM) and Qualcomm (NASDAQ:QCOM), but is not looking to sell its product unit. Intel's stock has dropped 31% due to missing the AI shift, while Taiwan Semiconductor (NYSE:TSM) excelled. Intel is considering converting its foundry business into an independent unit and has secured a U.S. chipmaking deal with Amazon (NASDAQ:AMZN). The semiconductor sector saw gains due to rate cuts and positive earnings from Micron Technology (NASDAQ:MU).

Portfolio Pulse from Anusuya Lahiri

September 27, 2024 | 3:23 pm

SKT

Tanger Outlet CEO discusses current shopping trends and consumer demand, providing insights into the retail sector's performance.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:22 pm

REGN

SNY

The FDA has approved Regeneron and Sanofi's Dupixent for treating inadequately controlled COPD with an eosinophilic phenotype, marking it as the first biologic medicine for this condition in the U.S. The approval is based on successful Phase 3 trials showing significant reductions in COPD exacerbations and improvements in lung function. This approval could impact approximately 300,000 U.S. patients.

Portfolio Pulse from Vandana Singh

September 27, 2024 | 3:17 pm

FLGC

The Cannabinoid Safety and Regulation Act (CSRA) introduced by Senator Ron Wyden aims to establish federal regulations for hemp-derived cannabinoids, including a ban on synthetic cannabinoids like Delta-8 THC. The bill proposes age restrictions, safety testing, and labeling standards, with the FDA overseeing compliance. The legislation has support from industry groups and companies like Flora Growth Corp. (NASDAQ:FLGC), but faces potential delays and backlash in Congress.

Portfolio Pulse from Patricio Liddle

September 27, 2024 | 3:16 pm

BMY

Bristol Myers Squibb announced positive results from the Phase 3b/4 PSORIATYK SCALP trial, demonstrating the efficacy of Sotyktu in treating moderate-to-severe scalp psoriasis. The trial showed Sotyktu's superiority over placebo in all primary and secondary endpoints at Week 16, with significant symptom improvement. The safety profile was consistent with previous studies.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:11 pm

BIDU

FXI

KWEB

Baidu Inc (NASDAQ:BIDU) shares surged 22% this week due to favorable macroeconomic developments in China, including the People's Bank of China's aggressive monetary easing measures. These measures, such as cutting the reserve requirement ratio and repo rates, are expected to benefit Baidu by increasing liquidity and capital access, aiding its growth in AI and other tech sectors. Baidu is also set to gain from potential fiscal stimulus plans in China, which could boost infrastructure spending in areas like AI and autonomous driving.

Portfolio Pulse from Henry Khederian

September 27, 2024 | 3:08 pm

HYLN

Hyliion's shares rose following the announcement that its KARNO linear generator qualifies under California's renewables portfolio standard.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:07 pm

CYTK

Cytokinetics presented new data from its SEQUOIA-HCM trial, showing that 83.8% of patients treated with aficamten experienced favorable effects compared to 39.3% on placebo. The trial demonstrated significant improvements in several cardiac health indices.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:02 pm

JBHT

NKLA

J.B. Hunt Transport Services Inc. has expanded its fleet with 20 Nikola Tre fuel cell electric vehicles to enhance sustainability solutions for its West Coast freight operations.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:01 pm

GNRC

Generac Holdings shares are experiencing an uptick in trading due to Hurricane Helene, as the company specializes in generators and power equipment.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:59 pm